The Longevity Boom Goes Public: Inside Vesalius Labs' CSE Debut

VANCOUVER, BC – October 29, 2026 – The Canadian Securities Exchange has long served as an incubator for industries operating on the cutting edge of mainstream capital markets. From early-stage mining exploration to the initial wave of legal cannabis, the CSE is historically where nascent, high-risk sectors go to find early liquidity. Today, the exchange is hosting the latest frontier in speculative venture capital: the longevity and regenerative medicine boom.

Vesalius Longevity Labs Inc. has officially closed its reverse takeover (RTO) of Sweet Earth Holdings Corporation, marking the end of a grueling 16-month trading halt. Expected to resume trading under the new ticker symbol "VLAB," the listing is a fascinating case study in how the architecture of public markets is adapting to the explosive, and often regulatory-complex, world of anti-aging and preventative healthcare.

Sweet Earth Holdings, which began its corporate life in 2018 as a hemp and cannabidiol (CBD) cultivator, had become a classic public market shell. By the end of 2024, the company was carrying an accumulated deficit of over $15 million with total assets hovering around a meager $27,000. It was a vehicle waiting for a new engine. That engine arrived in the form of Vesalius Longevity Labs, a private enterprise generating reported trailing revenue of $7.29 million prior to the merger, driven by the booming demand for peptide therapeutics and biologics.

Anatomy of a 16-Month Reverse Takeover

The mechanics of the Vesalius RTO offer a transparent look at how modern microcap transitions are engineered. Reverse takeovers are favored for their ability to bypass the lengthy, traditional initial public offering (IPO) process, but they are rarely simple. The 16-month trading halt—beginning in June 2025—underscores the intense regulatory scrutiny required to pivot a public shell from CBD cultivation into a global distributor of regenerative therapeutics.

Through a statutory amalgamation under British Columbia law, Sweet Earth acquired all issued and outstanding shares of Vesalius Canada and a specialized purpose vehicle (SPV). The resulting corporate structure leaves the newly minted Vesalius Longevity Labs Inc. with just over 100.8 million common shares outstanding, and roughly 117 million on a fully diluted basis. Former Vesalius Canada shareholders now control approximately 41.86% of the company, while SPV shareholders hold 29.91%.

To protect the newly formed entity from immediate market dumping, the architects of the deal have instituted massive, multi-year lockup and escrow agreements. Over 19.2 million shares held by related parties are locked in regulatory escrow, scheduled for a tiered release over 36 months. Another 49 million shares from former Vesalius Canada stakeholders face similar contractual resale restrictions extending out three years. Even the SPV shareholders have 26.2 million shares locked up for four months following the listing date.

These aggressive lockups are designed to signal long-term confidence to retail and institutional investors, ensuring that insiders cannot immediately liquidate their positions upon the resumption of trading. The transaction also included a substantial 3.9 million share finder's fee issued to Dagger Point Holdings Inc., an arm's-length advisory firm that helped orchestrate the capital markets transition.

Peptides, Biologics, and the Regulatory Line

While the financial engineering of the RTO is notable, the underlying business of Vesalius Longevity Labs is what truly reflects the shifting tides of global healthcare. The company operates a "business-to-doctor-to-consumer" (B2Doctor2Consumer) model. Instead of navigating the traditional, decade-long pharmaceutical approval pipeline, the enterprise operates in the rapidly expanding gray area of compounding pharmacies, wellness clinics, and telehealth.

The global peptide therapeutics market is projected to reach $106 billion by 2033, driven largely by the mainstream explosion of GLP-1 agonists and a growing consumer appetite for performance optimization. Vesalius is positioning itself to capture a slice of this market through its "Peptual" portfolio, which includes lyophilized and injectable pens distributed to licensed healthcare providers across North America, Europe, the UAE, and Latin America.

However, a critical distinction remains: the company is explicitly clear that its peptides and active pharmaceutical ingredients (APIs) are "not FDA-approved drug products." This places the operation squarely in the wellness and compounding space, a sector that is incredibly lucrative but increasingly vulnerable to regulatory crackdowns from agencies like the U.S. Food and Drug Administration and Health Canada.

To mitigate this systemic risk, Vesalius announced a pivotal exclusive manufacturing agreement with Celularity Inc. just hours before closing the RTO. The partnership aims to establish a U.S.-based, final-stage API manufacturing and supply platform for the Peptual brand. By aligning with Celularity to ensure current Good Manufacturing Practice (cGMP) standards, the longevity startup is building a defensive infrastructure. If regulatory bodies decide to tighten the rules around peptide compounding, the firm will already have a compliant, U.S.-based manufacturing pipeline in place—a significant competitive moat against smaller, less capitalized longevity clinics.

Capitalizing on the Longevity Economy

Beyond peptides, the newly public entity is aggressively expanding its footprint in regenerative biologics. The company holds distribution rights and a royalty-generating agreement tied to MuseCell Innovations, utilizing naturally occurring, pluripotent-like stem cells supported by extensive clinical research in Japan. It is a calculated bet that the future of medicine lies not just in managing disease, but in cellular regeneration and preventative optimization.

The organization is also targeting specific, underserved demographics within the longevity space. In October 2025, while still a private entity navigating the RTO process, Vesalius forged a strategic partnership with Wisp, a prominent women's telehealth provider. The collaboration is focused on co-developing peptide therapeutics tailored specifically for women, addressing a historical gender gap in longevity research and care.

Leading this multifaceted operation is a newly reconstituted board and executive team. Dr. Pradeep Albert, characterized by the company as a biotech veteran with deep formulation expertise, has taken the helm as Chief Executive Officer. The board is packed with heavyweights from the fintech, biotech, and consumer platform sectors, including Joel Leonoff, Kevin Mayer, and David Adelman. Their collective expertise suggests a corporate strategy heavily focused on digital scaling, consumer acquisition, and navigating complex regulatory environments.

As Vesalius Longevity Labs prepares to ring the bell on the CSE, it brings with it an estimated US$6.5 million in cash and a highly ambitious roadmap. The firm is attempting to bridge the gap between speculative anti-aging science and institutional public markets. Whether the B2Doctor2Consumer model can scale globally while navigating the shifting sands of FDA and Health Canada regulations remains to be seen. What is certain, however, is that the infrastructure of human health is being rebuilt, and public markets are increasingly eager to finance the architects.